U pstream Bio has dosed the first subject in the randomised Phase II trial of verekitug, an antibody antagonist targeting the thymic stromal lymphopoietin (TSLP) receptor, in individuals with chronic ...

Stage II chronic obstructive pulmonary disease, also known as moderate stage COPD. By stage II, your symptoms are usually no longer something you can just shrug off. They start to affect your ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in ...

Potential Positives. Initiation of a global Phase 2 clinical trial, VENTURE, to evaluate verekitug in COPD, marking an important step in expanding its clinical development program.

However, research among people with a moderate grade of COPD suggests life expectancy is lowered by 6.2 years. Making lifestyle changes and getting treatment may help slow the progression.

For comparison, the AUROC to estimate future moderate exacerbations when using one previous moderate COPD exacerbation within 12 months was 0.66 (sensitivity, 62.6%; specificity, 70.1%).

A recent national study revealed ongoing symptom burden and communication gaps in COPD care, and provided physicians with ...

An estimated 20 to 40% of patients with chronic obstructive pulmonary disease (COPD) have signs of eosinophilic inflammation, a condition that is characterized by an increased blood eosinophil ...